Pfizer (PFE) Stock Forecast & Price Target

Pfizer is supported by a large, diversified commercial base with roughly $60 billion in annual sales, led by prescription drugs and vaccines that now drive most revenue, while global reach and 40% international sales add resilience and exposure to emerging markets. Near-term fundamentals appear stronger because solid commercial execution and strong 1Q results could support a 2026 guidance upgrade, and the settlement of the Vyndaqel case should help keep revenues relatively stable until Vynda’s LOE. The main fundamental offset is slower longer-term growth, with post-LOE expansion uncertain around 2028, so positive pipeline data and continued base-business share gains are key to sustaining the constructive outlook.

Pfizer is facing a negative fundamental setup because its base business is under pressure from the loss of high-margin LOE products, weaker commercial execution on key marketed drugs such as Comirnaty, Paxlovid, Padcev, and Nurtec, and rising operating expenses needed to support pipeline growth. The excerpts also point to meaningful execution and pipeline risk, including disappointing clinical or regulatory outcomes for assets such as berobenatide, PF-08653945, PF'3945, PF'4404, and mevrometostat, while macro concerns like drug-pricing reform and tariff changes could further dampen investor sentiment. Despite roughly $60 billion in annual sales and 40% international revenue exposure, the combination of mix deterioration, margin compression toward 30% by 2029E, and limited M&A flexibility leaves the company with insufficient near-term catalysts to offset the $15-20 billion LOE hole.